FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361212334> ?p ?o ?g. }

• W4361212334 endingPage "69" @default.
• W4361212334 startingPage "62" @default.
• W4361212334 abstract "Background No previous controlled studies have been specifically designed or adequately powered to show the efficacy of topical oxybutynin for palmar hyperhidrosis by using quantitative measures. Objective To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH). Methods In a randomized controlled trial, Japanese patients with PPHH aged 12 years and older received either 20% OL (n = 144) or placebo (n = 140) on both palms once daily for 4 weeks. Palmar sweat volume was measured by the ventilated capsule method. For the primary outcome, response was defined as a reduction of sweat volume of at least 50% from baseline. Results At week 4, the responder rate for sweat volume was significantly higher in the 20% OL arm than in the placebo arm (52.8% vs 24.3%, respectively; treatment difference, 28.5% [95% CI, 17.7% to 39.3%]; P < .001). No serious adverse events occurred, and no adverse events led to treatment discontinuation. Limitations The treatment period was only 4 weeks. Conclusions In patients with PPHH, 20% OL is superior to placebo in reducing palmar sweat volume. No previous controlled studies have been specifically designed or adequately powered to show the efficacy of topical oxybutynin for palmar hyperhidrosis by using quantitative measures. To evaluate efficacy of 20% oxybutynin hydrochloride lotion (20% OL) in reducing palmar sweat volume in patients with primary palmar hyperhidrosis (PPHH). In a randomized controlled trial, Japanese patients with PPHH aged 12 years and older received either 20% OL (n = 144) or placebo (n = 140) on both palms once daily for 4 weeks. Palmar sweat volume was measured by the ventilated capsule method. For the primary outcome, response was defined as a reduction of sweat volume of at least 50% from baseline. At week 4, the responder rate for sweat volume was significantly higher in the 20% OL arm than in the placebo arm (52.8% vs 24.3%, respectively; treatment difference, 28.5% [95% CI, 17.7% to 39.3%]; P < .001). No serious adverse events occurred, and no adverse events led to treatment discontinuation. The treatment period was only 4 weeks. In patients with PPHH, 20% OL is superior to placebo in reducing palmar sweat volume." @default.
• W4361212334 created "2023-03-31" @default.
• W4361212334 creator A5000565136 @default.
• W4361212334 creator A5017707098 @default.
• W4361212334 creator A5051599427 @default.
• W4361212334 creator A5060059025 @default.
• W4361212334 creator A5078249218 @default.
• W4361212334 creator A5084894194 @default.
• W4361212334 date "2023-07-01" @default.
• W4361212334 modified "2023-10-09" @default.
• W4361212334 title "A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study" @default.
• W4361212334 cites W1567826565 @default.
• W4361212334 cites W1916511376 @default.
• W4361212334 cites W1965544584 @default.
• W4361212334 cites W1971360792 @default.
• W4361212334 cites W1976586886 @default.
• W4361212334 cites W1978330512 @default.
• W4361212334 cites W1984961017 @default.
• W4361212334 cites W1989338831 @default.
• W4361212334 cites W1995449113 @default.
• W4361212334 cites W2000978869 @default.
• W4361212334 cites W2011835490 @default.
• W4361212334 cites W2019323305 @default.
• W4361212334 cites W2026032783 @default.
• W4361212334 cites W2038915663 @default.
• W4361212334 cites W2051374626 @default.
• W4361212334 cites W2058562555 @default.
• W4361212334 cites W2068133922 @default.
• W4361212334 cites W2089791513 @default.
• W4361212334 cites W2096991001 @default.
• W4361212334 cites W2130690736 @default.
• W4361212334 cites W2151656499 @default.
• W4361212334 cites W2168499550 @default.
• W4361212334 cites W2170874530 @default.
• W4361212334 cites W2313053302 @default.
• W4361212334 cites W2507515498 @default.
• W4361212334 cites W2529904056 @default.
• W4361212334 cites W2562382738 @default.
• W4361212334 cites W2575902862 @default.
• W4361212334 cites W2622220612 @default.
• W4361212334 cites W2725768449 @default.
• W4361212334 cites W2735914148 @default.
• W4361212334 cites W2977502002 @default.
• W4361212334 cites W3018419447 @default.
• W4361212334 cites W3091442097 @default.
• W4361212334 cites W3110777954 @default.
• W4361212334 cites W3206449521 @default.
• W4361212334 cites W4225774966 @default.
• W4361212334 doi "https://doi.org/10.1016/j.jaad.2023.03.025" @default.
• W4361212334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36990320" @default.
• W4361212334 hasPublicationYear "2023" @default.
• W4361212334 type Work @default.
• W4361212334 citedByCount "3" @default.
• W4361212334 countsByYear W43612123342023 @default.
• W4361212334 crossrefType "journal-article" @default.
• W4361212334 hasAuthorship W4361212334A5000565136 @default.
• W4361212334 hasAuthorship W4361212334A5017707098 @default.
• W4361212334 hasAuthorship W4361212334A5051599427 @default.
• W4361212334 hasAuthorship W4361212334A5060059025 @default.
• W4361212334 hasAuthorship W4361212334A5078249218 @default.
• W4361212334 hasAuthorship W4361212334A5084894194 @default.
• W4361212334 hasConcept C126322002 @default.
• W4361212334 hasConcept C141071460 @default.
• W4361212334 hasConcept C142724271 @default.
• W4361212334 hasConcept C168563851 @default.
• W4361212334 hasConcept C197934379 @default.
• W4361212334 hasConcept C202061045 @default.
• W4361212334 hasConcept C204787440 @default.
• W4361212334 hasConcept C27081682 @default.
• W4361212334 hasConcept C2777844464 @default.
• W4361212334 hasConcept C2778650131 @default.
• W4361212334 hasConcept C2778941218 @default.
• W4361212334 hasConcept C2780986958 @default.
• W4361212334 hasConcept C2991744798 @default.
• W4361212334 hasConcept C42219234 @default.
• W4361212334 hasConcept C63398376 @default.
• W4361212334 hasConcept C71924100 @default.
• W4361212334 hasConcept C98274493 @default.
• W4361212334 hasConceptScore W4361212334C126322002 @default.
• W4361212334 hasConceptScore W4361212334C141071460 @default.
• W4361212334 hasConceptScore W4361212334C142724271 @default.
• W4361212334 hasConceptScore W4361212334C168563851 @default.
• W4361212334 hasConceptScore W4361212334C197934379 @default.
• W4361212334 hasConceptScore W4361212334C202061045 @default.
• W4361212334 hasConceptScore W4361212334C204787440 @default.
• W4361212334 hasConceptScore W4361212334C27081682 @default.
• W4361212334 hasConceptScore W4361212334C2777844464 @default.
• W4361212334 hasConceptScore W4361212334C2778650131 @default.
• W4361212334 hasConceptScore W4361212334C2778941218 @default.
• W4361212334 hasConceptScore W4361212334C2780986958 @default.
• W4361212334 hasConceptScore W4361212334C2991744798 @default.
• W4361212334 hasConceptScore W4361212334C42219234 @default.
• W4361212334 hasConceptScore W4361212334C63398376 @default.
• W4361212334 hasConceptScore W4361212334C71924100 @default.
• W4361212334 hasConceptScore W4361212334C98274493 @default.
• W4361212334 hasIssue "1" @default.
• W4361212334 hasLocation W43612123341 @default.
• W4361212334 hasLocation W43612123342 @default.

• next